ArticleInfection
Intracellular activity of vancomycin and Ly333328, a new semisynthetic glycopeptide, against methicillin-resistant Staphylococcus aureus.
Article in Infection. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 18 citations in OpenAlex.
- Review
- Vancomycin-Loaded Isogenous Membrane Vesicles for Macrophage Activation and Intracellular Methicillin-ResistantInternational journal of nanomedicine · 2025Article
- Shock wave assisted intracellular delivery of antibiotics against bone infection withJournal of orthopaedic translation · 2024Article
- Metal-Organic Framework-Based Nanomedicines for the Treatment of Intracellular Bacterial Infections.Pharmaceutics · 2023Review
- Intracellular Habitation ofBiomedicines · 2022Review
- Plectasin shows intracellular activity against Staphylococcus aureus in human THP-1 monocytes and in a mouse peritonitis model.Antimicrobial agents and chemotherapy · 2009Article
- Mixed-lipid storage disorder induced in macrophages and fibroblasts by oritavancin (LY333328), a new glycopeptide antibiotic with exceptional cellular accumulation.Antimicrobial agents and chemotherapy · 2005Article
- Quantitative analysis of gentamicin, azithromycin, telithromycin, ciprofloxacin, moxifloxacin, and oritavancin (LY333328) activities against intracellular Staphylococcus aureus in mouse J774 macrophages.Antimicrobial agents and chemotherapy · 2003Article
- Pharmacodynamics of oritavancin (LY333328) in a neutropenic-mouse thigh model of Staphylococcus aureus infection.Antimicrobial agents and chemotherapy · 2003Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The activity of vancomycin and Ly333328, a new semisynthetic glycopeptide, against eight strains of Staphylococcus aureus showing various susceptibilities to methicillin and ciprofloxacin was examined using a colony count method. We compared the growth of strains ingested by polymorphonuclear leucocytes and non-ingested strains. MICs of vancomycin and Ly333328 against staphylococci resistant and susceptible to methicillin were 2 mg/l and 2-4 mg/l, respectively. Against all the tested extracellular staphylococci, vancomycin had only bacteriostatic activity, whereas Ly333328 showed cidal activity at 10 MIC. Against ingested staphylococci, vancomycin had nearly no activity compared with the controls, regardless of the concentration of the drug. Ly333328 at concentrations of 1 MIC and above was highly active against ingested staphylococci regardless of their susceptibility pattern. The results suggest that Ly333328 in contrast to vancomycin is active against intracellular S. aureus.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.